Endo International Acquires Somar

Endo International has signed an agreement to acquire México’s Grupo Farmaceútico Somar, a specialty pharmaceutical firm based in México City, in a deal that the Irish drugmaker hopes will help it expand further into Latin America, Endo told Drug Daily Bulletin.

In a separate press release, Endo President and CEO Rajiv De Silva says the firm plans to take advantage of Somar’s sales team and manufacturing facilities in Ajusco, Chalco, Del Valle and Piedras Negras, as well as its “robust pipeline,” which has 60 products set to reach the market in the next three years.

The company lists 48 marketed products across 14 therapeutic areas, including antivirals, weight loss, nervous system, analgesics and dermatology. Somar’s business focuses primarily on private label and traditional generics, as well as products for government procurement, branded generics in dermatology and infectious diseases, and over-the-counter (OTC) women’s health and childcare products. The firm generated $100 million in revenue last year.

The deal is expected to close in the third quarter. — Lena Freund

Subscribe to Drug Industry Daily for complete coverage of the pharmaceutical industry. Click here for more information.